FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 273 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR What to Know About Treatment Options Before and After Surgery for... November 7, 2023 FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... April 9, 2024 Educators Raise Money in Memory of Teacher Who Dedicated Herself to... January 19, 2021 Ending smoking could free up 75,000 GP appointments each month March 7, 2023 Load more HOT NEWS Changes to chromosomes impact how children’s brain tumours respond to treatment Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients... Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer Tovorafenib Approved for Some Children with Low-Grade Glioma
